Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mechlorethamine
Drug ID BADD_D01359
Description A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
Indications and Usage For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion.
Marketing Status Prescription
ATC Code L01AA05
DrugBank ID DB00888
KEGG ID D07671
MeSH ID D008466
PubChem ID 4033
TTD Drug ID D03SSE
NDC Product Code Not Available
Synonyms Mechlorethamine | Chlormethine | Bis(2-chloroethyl)methylamine | Mustine | Nitrogen Mustard | Chlorethazine | Methylchlorethamine | Cloramin | Embichin | Mechlorethamine Hydrochloride | Hydrochloride, Mechlorethamine | Mechlorethamine Hydrochloride N-Oxide | Hydrochloride N-Oxide, Mechlorethamine | Mechlorethamine Hydrochloride N Oxide | N-Oxide, Mechlorethamine Hydrochloride | NSC-762 | NSC 762 | NSC762 | Mechlorethamine Oxide | Mitomen | Mustargen | Nitrogranulogen | Nitromin | NSC-10107 | NSC 10107 | NSC10107 | Caryolysine | Mechlorethamine N-Oxide | Mechlorethamine N Oxide | Nitrogen Mustard N-Oxide | N-Oxide, Nitrogen Mustard | Nitrogen Mustard N Oxide
Chemical Information
Molecular Formula C5H11Cl2N
CAS Registry Number 51-75-2
SMILES CN(CCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Joint stiffness15.01.02.0030.000533%Not Available
Leukopenia01.02.02.001--Not Available
Lip swelling07.05.04.005; 23.04.01.007; 10.01.05.0050.000533%Not Available
Lung disorder22.02.07.0010.000533%Not Available
Lymphadenopathy01.09.01.0020.000533%Not Available
Lymphopenia01.02.02.002--Not Available
Malaise08.01.01.0030.005328%
Mediastinum neoplasm16.19.07.001; 22.09.03.003--Not Available
Memory impairment19.20.01.003; 17.03.02.0030.001066%
Menstruation delayed21.01.02.003; 05.05.01.010--Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Mycosis fungoides23.07.04.008; 16.17.03.001; 01.11.03.0010.004529%Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasopharyngitis22.07.03.002; 11.01.13.0020.003197%Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.0010.000208%Not Available
Nephrolithiasis20.04.01.0020.000533%
Nervousness19.06.02.0030.000799%Not Available
Night sweats23.02.03.006; 08.01.03.0310.000799%Not Available
Oligomenorrhoea21.01.02.004; 05.05.01.011--Not Available
Oliguria20.01.03.004--Not Available
Pain08.01.08.0040.005062%
Pain in extremity15.03.04.0100.003197%
Pain of skin23.03.03.0030.002664%
Pancytopenia01.03.03.003--Not Available
Paraesthesia17.02.06.005--
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pharyngitis streptococcal22.07.04.001; 11.02.06.0020.000533%Not Available
Platelet count normal13.01.04.007--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages